MediciNova (NASDAQ:MNOV) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of MediciNova (NASDAQ:MNOV) in a research note issued on Friday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

MediciNova Trading Up 9.0 %

MediciNova stock opened at $1.69 on Friday. The firm has a market capitalization of $82.89 million, a price-to-earnings ratio of -9.94 and a beta of 0.72. MediciNova has a 1-year low of $1.12 and a 1-year high of $2.38. The firm has a 50 day simple moving average of $1.42 and a 200 day simple moving average of $1.41.

MediciNova (NASDAQ:MNOV) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01. On average, equities research analysts forecast that MediciNova will post -0.23 EPS for the current year.

MediciNova Company Profile

MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.